Magnetic Field Rotating / PD-L1 Cancer Research Results

MFrot, Magnetic Field Rotating: Click to Expand ⟱
Features:
Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation)
Targets affected are mostly the same as for Magnet fields
Main differences
- may enhance the EPR effect allowing targeting of drugs to cancer cells
- acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media)
- research for use in nano surgery, and mechanical destruction of cancer cells
- continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells
- RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells)

Pathways:
- induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing)
- ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓,
- Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK,
- Synergies: < Others(review target notes), Neuroprotective, Cognitive,

- Selectivity: Cancer Cells vs Normal Cells

Rotating Magnetic Fields
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS (tumor-selective oxidative stress) ↑ ROS (P→R); sustained to cytotoxicity (G) ↔ minimal change or transient ↑ without injury (P→R) P, R, G Primary stress amplifier Oncomagnetic reports emphasize selective tumor ROS increase with normal-cell sparing in comparable exposure conditions
2 Mitochondrial ETC inhibition (Complex I/NADH:ubiquinone) ↓ Complex I / respiration (P→R) ↔ limited effect (P→R) P, R Bioenergetic collapse trigger Rotating/spinning fields are proposed to disrupt mitochondrial electron flow, driving ROS elevation upstream of ΔΨm loss
3 Ca²⁺ signaling (ER–mitochondria Ca²⁺ transfer / mitochondrial Ca²⁺ load) ↑ Ca²⁺ dysregulation (P→R) contributing to mitochondrial failure (G) ↔ buffered Ca²⁺ homeostasis (P→R) P, R, G Amplifies ETC/ROS-driven toxicity RMF-driven mitochondrial stress can propagate via Ca²⁺ transfer to accelerate ΔΨm loss and pro-death ER stress in tumor cells while sparing normal cells
4 Mitochondrial permeability transition pore (MPTP) ↑ sustained MPTP opening (R→G) ↔ resistant to opening P, R, G Mitochondrial point-of-no-return RMF-enhanced ROS and Ca²⁺ loading promote persistent MPTP opening in tumor mitochondria, driving energetic collapse and apoptosis while normal cells remain below the opening threshold
5 ΔΨm / mitochondrial membrane integrity ↓ ΔΨm (R); progresses (G) ↔ preserved R, G Mitochondrial failure threshold Matches the “energy factory” targeting concept described in Oncomagnetic mechanism narratives
6 GSH depletion ↓ GSH (R→G) ↔ maintained R, G Loss of redox buffering Cancer-selective inability to restore GSH is a key discriminator vs normal cells
7 NRF2 response (selectivity gate) ↔ delayed/insufficient NRF2 (R→G) ↑ NRF2 (R→G) R, G Adaptive protection Normal-cell sparing is consistent with competent NRF2-driven antioxidant defense
8 ER stress / UPR (CHOP commitment) ↑ ER stress (R); CHOP/apoptotic UPR (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis failure ETC/ROS stress propagates to ER; commitment vs resolution diverges by cell robustness
9 DNA damage (oxidative; checkpoint markers) ↑ DNA damage (R→G) ↔ or repaired (G) R, G Checkpoint stress Interpreted as ROS-mediated consequence; reported as increased damage markers in some translational datasets
10 LDH / glycolytic vulnerability ↓ LDH performance / ↓ glycolytic flux (R→G) ↔ metabolic flexibility R, G Metabolic choke Cancer glycolysis becomes unstable when NADH/NAD+ and redox buffering are stressed
11 TrxR / thioredoxin system overload ↓ reserve (R→G) ↔ preserved R, G Parallel antioxidant collapse Useful when GSH data are mixed; TrxR can be the limiting system under sustained ROS 
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.
PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Migration ⓘ

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

PD-L1↑, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity∅, 2,  
Total Targets: 1

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:192  Target#:243  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page